AstraZeneca to buy US-listed Fusion Pharma for $2bn
Fusion Pharmaceuticals Inc
$21.55
11:00 25/03/25
0.00%
$0.00
AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
AstraZeneca
11,254.00p
17:15 31/03/25
-1.42%
-162.00p
FTSE 100
8,582.81
16:59 31/03/25
n/a
n/a
FTSE 350
4,675.03
16:49 31/03/25
n/a
n/a
FTSE All-Share
4,623.62
17:14 31/03/25
n/a
n/a
Pharmaceuticals & Biotechnology
21,522.38
16:49 31/03/25
-1.26%
-275.63
Fusion specialises in radioconjugates, which combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells.
AstraZeneca will pay $21 a share for Fusion, a premium of more than 97% to the US-listed company's closing price on Monday and a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4bn.
Reporting by Frank Prenesti for Sharecast.com